Mirabegron Glenmark

Mirabegron, the active ingredient in Mirabegron Glenmark, is a β3‑adrenergic receptor agonist presented as an oral tablet for prescription use. It relaxes the detrusor muscle of the urinary bladder, helping patients with overactive bladder symptoms such as urgency, frequency and urge incontinence.

GNH USA supplies Mirabegron Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. The product meets EU market standards and is manufactured under strict GMP conditions.

Mirabegron is indicated for conditions affecting bladder storage function, primarily overactive bladder and related symptoms. - Overactive bladder: reduces urinary urgency and frequency by increasing bladder capacity. - Urinary urgency: lessens the sudden need to void, improving daily comfort. - Urinary frequency: decreases the number of daytime voids through detrusor relaxation. - Urge incontinence: helps prevent involuntary leakage by stabilizing bladder storage.

Adverse reactions reported with Mirabegron Glenmark span from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Hypertension: increase in blood pressure. - Nasopharyngitis: common cold‑like symptoms. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe hypertension: marked elevation of blood pressure requiring medical attention. - Urinary retention: difficulty emptying the bladder. - Cardiac arrhythmia: irregular heart rhythm observed in rare cases.

Before prescribing Mirabegron Glenmark, clinicians should consider several safety precautions. - Assess blood pressure: monitor baseline and periodic readings due to potential hypertensive effect. - Evaluate renal function: dose adjustment may be needed in severe impairment. - Review concomitant antihypertensives: risk of reduced efficacy or additive blood pressure changes. - Caution in patients with uncontrolled hypertension: avoid initiating therapy until blood pressure is controlled. - Avoid use in patients with known hypersensitivity to mirabegron or excipients. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Mirabegron can alter the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirabegron exposure. - Strong CYP2D6 inducers (e.g., rifampin): may reduce mirabegron efficacy. - Combined use with anticholinergics for bladder control: may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: mirabegron may attenuate blood pressure‑lowering effects. - Diuretics: monitor for changes in fluid balance and electrolytes. - Warfarin: occasional reports of altered INR; check coagulation parameters.